In Oncology Drug Boom, Can Next-Gen Cytotoxics Fit In?
The drug industry has placed a bull's eye on the field of oncology as a key therapeutic area, but not all oncology players are created equal.
You may also be interested in...
The U.S. biotechs, which are independent but share founders and investors, raise a combined $94.5 million from the Russian sovereign fund and U.S. venture firms.
Selecta Biosciences Inc. and BIND Biosciences Inc., two Boston-based -- and heretofore low-profile -- young biotechs, have raised a combined $94.5 million from a mix of equity financings and strategic alliances with one of the world's largest investment funds dedicated to nanotechnology, Rusnano, and other investors
Biotech's nanotechnology platform enables earlier detection of cancers and distant metastases, as well as targeted drug delivery.